Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16281515 | 0.91 | TSHR (0.39) | TSHRLMNATHRB | |
| SCHEMBL8322880 | 0.88 | TSHR (0.44) | TSHRLMNATHRB | |
| SCHEMBL8180002 | 0.88 | TSHR (0.44) | TSHRLMNATHRB | |
| SCHEMBL17739937 | 0.82 | — | — | |
| SCHEMBL7769057 | 0.80 | — | — | |
| SCHEMBL3482093 | 0.79 | — | — | |
| SCHEMBL5819879 | 0.79 | — | — | |
| SCHEMBL3482487 | 0.77 | — | — | |
| SCHEMBL17088166 | 0.76 | TSHR (0.38) | TSHRLMNATHRB | |
| SCHEMBL10813563 | 0.75 | TSHR (0.36) | TSHRLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| EP-3784718-B1 | PROCESS FOR THE PREPARATION OF HYDROXYL-FUNCTIONALIZED POLYETHERPOLYSILOXANE BLOCK COPOLYMERS | HENKEL AG & CO KGAA (DE) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024083861-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | SELABTEC SCIENCES, SLU (ES) | 2024-04-25 | — | — | WO | disclosed |
| CN-114096590-B | UV and/or thermally curable silicone-based materials and formulations | 汉高股份有限及两合公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2024074604-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | INSTITUTO BIOMAR, S.A (ES) | 2024-04-11 | — | — | WO | disclosed |
| US-20220411634-A1 | SILICONE FORMULATION WITH HIGH TEMPERATURE STABILITY AND CLARITY | HENKEL AG & CO. KGAA (DE) | 2022-12-29 | — | — | US | disclosed |
| EP-4108726-A1 | SILICONE FORMULATION WITH HIGH TEMPERATURE STABILITY AND CLARITY | Henkel AG & Co. KGaA (DE) | 2022-12-28 | — | — | EP | disclosed |
| US-11326027-B2 | Process for the preparation of hydroxyl-functionalized polysiloxanes | HENKEL AG & CO. KGAA (DE) | 2022-05-10 | — | — | US | disclosed |
| CN-114096590-A | UV and/or thermally curable silicone-based materials and formulations | 汉高知识产权控股有限责任公司 | 2022-02-25 | — | — | CN | disclosed |
| EP-3953412-A1 | UV AND/OR HEAT CURABLE SILICONE BASED MATERIALS AND FORMULATIONS | Henkel IP & Holding GmbH (DE) | 2022-02-16 | — | — | EP | disclosed |
| WO-2014149494-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | LIXTE BIOTECHNOLOGY, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2054427-A2 | AVERMECTIN DERIVATIVES | Bayer CropScience AG (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008080988-A2 | CYCLOPENTANONE DERIVATIVES, METHOD OF SYNTHESIS AND USES THEREOF | NEUROPHARMA, S.A. (ES) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008019784-A2 | AVERMECTIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007054517-A1 | SYNTESIS OF TETRODOTOXIN , ITS ANALOGUES AND INTERMEDIATES THEREOF | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-18 | — | — | WO | disclosed |
| EP-1412346-A1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | Bayer CropScience AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003010155-A1 | METHOD FOR PRODUCING NOVEL SPINOSYN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2003-02-06 | — | — | WO | disclosed |
| EP-1114824-B1 | Process for preparing 1,3-dihalo-1,1,3,3-tetraorgano disilioxanes | WACKER CHEMIE GMBH (DE) | 2001-12-12 | — | — | EP | disclosed |
| US-6284907-B1 | REACTING HYDROGEN HALIDE WITH THE CORRESPONDING 1,3-DIHYDRO-1,1,3,3-TETRA(ORGANYL)DISILOXANES; CATALYST SELECTED FROM TRANSITION METALS OF THE 8TH SUBGROUP OF THE PERIODIC TABLE OF THE ELEMENTS, OR COMPOUNDS OR COMPLEXES | WACKER-CHEMIE GMBH (DE) | 2001-09-04 | — | — | US | disclosed |
| EP-1114824-A1 | Process for preparing 1,3-dihalo-1,1,3,3-tetraorgano disilioxanes | Wacker-Chemie GmbH (DE) | 2001-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11326027-B2 | Process for the preparation of hydroxyl-functionalized polysiloxanes | C9, HACL2, ADH1C | TSHR 1408/4885LMNA 929/4885THRB 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.